Amylin, Takeda to terminate pramlintide/metreleptin development

The companies’ decision was supported by the reevaluation of pramlintide/metreleptin program which had been in Phase 2 development as a twice-a-day injection formulation as a treatment for obesity.

Amylin and Takeda expect to carry forward the investigation of other assets targeting obesity and related indications as per the terms of their existing collaboration agreement.

Amylin R&D senior vice president Christian Weyer said advances in peptide engineering and delivery may help them leverage this biology to develop a therapy with less frequent dosing.

"With our partner, Takeda, we look forward to continuing to explore new options for the obesity market," Weyer said.